Puma Biotechnology Q2 FY26 GAAP net income rises 38.98% to $8.2 million; revenue increases 7.82% to $56.5 million
PBYI•Q2 results and updated 2026 outlook
Puma Biotechnology posted GAAP net income of USD 8.2 million in Q2 2026, up 38.98% year over year.
Total revenue rose 7.82% to USD 56.5 million, led by net product revenue of USD 53.6 million; royalty revenue was USD 2.9 million.
Operating costs and expenses increased 6.77% to USD 48.9 million, reflecting higher R&D spend of USD 18.9 million.
The company raised its full-year 2026 outlook for net product revenue to USD 205-209 million and lifted net income guidance to USD 17-20 million.
CEO Alan H. Auerbach cited rising demand for NERLYNX, with ALISCA-Lung2 enrollment initiation targeted for Q3 2026.
